Leucine-rich repeat kinase 2 (LRRK2)-deficient rats exhibit renal tubule injury and perturbations in metabolic and immunological homeostasis
about
Emerging preclinical pharmacological targets for Parkinson's diseaseProgressive dopaminergic alterations and mitochondrial abnormalities in LRRK2 G2019S knock-in miceLRRK2 at the interface of autophagosomes, endosomes and lysosomesLRRK2 inhibitors and their potential in the treatment of Parkinson's disease: current perspectivesParkinson's disease: animal models and dopaminergic cell vulnerabilityModelling idiopathic Parkinson disease as a complex illness can inform incidence rate in healthy adults: the PREDIGT scoreHolocranohistochemistry enables the visualization of α-synuclein expression in the murine olfactory system and discovery of its systemic anti-microbial effectsLeucine-Rich Repeat Kinase 2 (Lrrk2) Deficiency Diminishes the Development of Experimental Autoimmune Uveitis (EAU) and the Adaptive Immune Response.Leucine-rich repeat kinase 2 deficiency is protective in rhabdomyolysis-induced kidney injury.Leucine-rich Repeat Kinase 2 (LRRK2) Pharmacological Inhibition Abates α-Synuclein Gene-induced Neurodegeneration.LRRK2 and ubiquitination: implications for kinase inhibitor therapyNo Association Between rs7077361 in ITGA8 and Parkinson's Disease in Sweden.A strategy for the generation, characterization and distribution of animal models by The Michael J. Fox Foundation for Parkinson's ResearchLoss of leucine-rich repeat kinase 2 (LRRK2) in rats leads to progressive abnormal phenotypes in peripheral organsThe function of orthologues of the human Parkinson's disease gene LRRK2 across species: implications for disease modelling in preclinical research.Pathogenic LRRK2 variants are gain-of-function mutations that enhance LRRK2-mediated repression of β-catenin signalingTargeting leucine-rich repeat kinase 2 in Parkinson's disease.Structural biology of the LRRK2 GTPase and kinase domains: implications for regulation.LRRK2 Kinase Inhibition as a Therapeutic Strategy for Parkinson's Disease, Where Do We Stand?LRRK2 and the Immune System.Models of LRRK2-Associated Parkinson's Disease.Targeting LRRK2 in Parkinson's disease: an update on recent developments.The G2019S LRRK2 mutation increases myeloid cell chemotactic responses and enhances LRRK2 binding to actin-regulatory proteins.Selective LRRK2 kinase inhibition reduces phosphorylation of endogenous Rab10 and Rab12 in human peripheral mononuclear blood cells.Altered Expression of EPO Might Underlie Hepatic Hemangiomas in LRRK2 Knockout Mice.Effect of selective LRRK2 kinase inhibition on nonhuman primate lung.New developments in genetic rat models of Parkinson's disease.
P2860
Q26764724-C9E13A63-6E4A-4D59-9AFF-7F7C26A2C4F6Q27308060-FF6ACEBD-F9B6-4E77-ADB8-87C3DBF2A2DCQ28078248-67773EAA-288C-4E80-8DD1-89AA6B2E80BEQ28078899-734FB7E6-7C30-4198-9652-3471C3C8C177Q28080503-B16B6B7F-329F-4306-A1C5-9E031DA19D3FQ29048624-D166EA50-0F4D-45CA-A844-80D2B074B95AQ33734084-F8330D8D-39C2-4F20-9939-B24EF19F8A6DQ35661537-03D9B949-D06E-487D-ACC5-44BDA226DCBDQ35766417-BB5791FE-55F1-4212-BE4C-39790C3B525EQ35925767-73EA36A2-8750-4566-A809-80C8C5370523Q36185165-6974C2FA-7537-4B37-908C-66B9C5F35593Q37195775-79A96D2F-C833-41B8-AE4D-845E82BD1C7BQ37287403-B08444AD-315C-4215-8A2F-11618742E4AFQ37308940-BAA9234E-4ADD-44AA-B5A0-014E5D3772BDQ37513500-E049FDA0-2660-469D-BB9B-EE143F5924C6Q37595673-BBDEDECC-607A-4BE8-856E-9ABCACD5FEADQ38160939-1CC3DBDF-F15D-49FE-A1CA-BB524E93D8F2Q38213378-764775E2-B344-42CB-A25F-20BB3C1B27A6Q38620229-47F37AFF-63C6-475A-9075-B1B120D5BCA0Q39206438-B3D863B4-74DB-48FE-BB16-928ACB10847FQ39206443-C39D6949-D0EE-43E6-B324-5DA250D0D080Q39263032-09F222EF-6991-48A0-8350-996C72121A5BQ41374126-2FDA6844-965E-4ABC-A5CB-80029AC82B24Q41579661-D1E0BCB9-E91D-4D86-9B30-ECA00BD03FF8Q42369410-846F0B60-DCED-42CF-998E-A28C07C3C97AQ46777308-5A680F57-463E-4B31-A02C-002E14102078Q48502440-2DFF1BC8-DD67-4CA7-803E-5EA8834E3675
P2860
Leucine-rich repeat kinase 2 (LRRK2)-deficient rats exhibit renal tubule injury and perturbations in metabolic and immunological homeostasis
description
2013 nî lūn-bûn
@nan
2013 թուականին հրատարակուած գիտական յօդուած
@hyw
2013 թվականին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Leucine-rich repeat kinase 2 ( ...... and immunological homeostasis
@ast
Leucine-rich repeat kinase 2 ( ...... and immunological homeostasis
@en
Leucine-rich repeat kinase 2 ( ...... and immunological homeostasis
@nl
type
label
Leucine-rich repeat kinase 2 ( ...... and immunological homeostasis
@ast
Leucine-rich repeat kinase 2 ( ...... and immunological homeostasis
@en
Leucine-rich repeat kinase 2 ( ...... and immunological homeostasis
@nl
prefLabel
Leucine-rich repeat kinase 2 ( ...... and immunological homeostasis
@ast
Leucine-rich repeat kinase 2 ( ...... and immunological homeostasis
@en
Leucine-rich repeat kinase 2 ( ...... and immunological homeostasis
@nl
P2093
P2860
P3181
P1433
P1476
Leucine-rich repeat kinase 2 ( ...... and immunological homeostasis
@en
P2093
Andrew J Olaharski
Daniel Ness
Douglas Sharpnack
Elizabeth F Brigham
Richard J Brennan
Shyra Gardai
Victor J Johnson
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0066164
P407
P577
2013-01-01T00:00:00Z